David Gonzalez

David Gonzalez

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Seminars in Oncology
Verified
Journal Article
Open access
PDF file
ETTORE CAPOLUONGOETTORE CAPOLUONGO
ETTORE CAPOLUONGO
GEGillian Ellison
Gillian Ellison
JLJosé Antonio López-Guerrero
José Antonio López-Guerrero
FPFrederique Penault-Llorca
Frederique Penault-Llorca
MLMarjolijn J.L. Ligtenberg
Marjolijn J.L. Ligtenberg
DGDavid Gonzalez
David Gonzalez
The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum–sensitive relapsed high–grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with ovarian cancer. Ovarian cancer patients are now being referred for BRCA1/2 genetic testing for treatment decisions, in addition to familial risk estimation, and irrespective of a family history of breast or ovarian cancer. Furthermore, testing of tumor samples to identify the estimated 3%–9% of patients with somatic BRCA1/2 mutations who, in addition to germline carriers, could benefit from PARPi therapy is also now being considered. This new testing paradigm poses some challenges, in particular the technical and analytical difficulties of analyzing chemically challenged DNA derived from formalin–fixed, paraffin–embedded specimens. The current manuscript reviews some of these challenges and technical recommendations to consider when undertaking BRCA1/2 testing in tumor tissue samples to detect both germline and somatic BRCA1/2 mutations. Also provided are considerations for incorporating genetic analysis of ovarian tumor samples into the patient pathway and ethical requirements.

1 November 2019 in European Journal of Cancer
Verified
Journal Article
Open access
SGSally L. George
Sally L. George
EIElisa Izquierdo
Elisa Izquierdo
JCJames Campbell
James Campbell
EKEleni Koutroumanidou
Eleni Koutroumanidou
PPPaula Proszek
Paula Proszek
LCLouis Chesler
Louis Chesler
For children with cancer, the clinical integration of precision medicine to enable predictive biomarker-based therapeutic stratification is urgently needed. We have developed a hybrid-capture next-generation sequencing (NGS) panel, specifically designed to detect genetic alterations in paediatric solid tumours, which gives reliable results from as little as 50 ng of DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue. In this study, we offered an NGS panel, with clinical reporting via a molecular tumour board for children with solid tumours. Furthermore, for a cohort of 12 patients, we used a circulating tumour DNA (ctDNA)-specific panel to sequence ctDNA from matched plasma samples and compared plasma and tumour findings. A total of 255 samples were submitted from 223 patients for the NGS panel. Using FFPE tissue, 82% of all submitted samples passed quality control for clinical reporting. At least one genetic alteration was detected in 70% of sequenced samples. The overall detection rate of clinically actionable alterations, defined by modified OncoKB criteria, for all sequenced samples was 51%. A total of 8 patients were sequenced at different stages of treatment. In 6 of these, there were differences in the genetic alterations detected between time points. Sequencing of matched ctDNA in a cohort of extracranial paediatric solid tumours also identified a high detection rate of somatic alterations in plasma. We demonstrate that tailored clinical molecular profiling of both tumour DNA and plasma-derived ctDNA is feasible for children with solid tumours. Furthermore, we show that a targeted NGS panel-based approach can identify actionable genetic alterations in a high proportion of patients.

4 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLChey Loveday
Chey Loveday
KLKevin Litchfield
Kevin Litchfield
PPPaula Z. Proszek
Paula Z. Proszek
ACAlex J. Cornish
Alex J. Cornish
FSFlavia Santo
Flavia Santo
CTClare Turnbull
Clare Turnbull
While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity to platinum chemotherapy, ~10% are platinum resistant. To gain insight into the underlying mechanisms, we undertake whole exome sequencing and copy number analysis in 40 tumours from 26 cases with platinum-resistant TGCT, and combine this with published genomic data on an additional 624 TGCTs. We integrate analyses for driver mutations, mutational burden, global, arm-level and focal copy number (CN) events, and SNV and CN signatures. Albeit preliminary and observational in nature, these analyses provide support for a possible mechanistic link between early driver mutations in RAS and KIT and the widespread copy number events by which TGCT is characterised.

15 May 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
TCthe EuroClonality-NGS Consortium
the EuroClonality-NGS Consortium
ALAnton W. Langerak
Anton W. Langerak
MBMonika Brüggemann
Monika Brüggemann
FDFrédéric Davi
Frédéric Davi
NDNikos Darzentas
Nikos Darzentas
KSKostas Stamatopoulos
Kostas Stamatopoulos
Analysis and interpretation of Ig and TCR gene rearrangements in the conventional, low-throughput way have their limitations in terms of resolution, coverage, and biases. With the advent of high-throughput, next-generation sequencing (NGS) technologies, a deeper analysis of Ig and/or TCR (IG/TR) gene rearrangements is now within reach, which impacts on all main applications of IG/TR immunogenetic analysis. To bridge the generation gap from low- to high-throughput analysis, the EuroClonality-NGS Consortium has been formed, with the main objectives to develop, standardize, and validate the entire workflow of IG/TR NGS assays for 1) clonality assessment, 2) minimal residual disease detection, and 3) repertoire analysis. This concerns the preanalytical (sample preparation, target choice), analytical (amplification, NGS), and postanalytical (immunoinformatics) phases. Here we critically discuss pitfalls and challenges of IG/TR NGS methodology and its applications in hemato-oncology and immunology.

22 September 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DAD.M. Allin
D.M. Allin
RSR. Shaikh
R. Shaikh
PCP. Carter
P. Carter
KTK. Thway
K. Thway
MSM.T.A. Sharabiani
M.T.A. Sharabiani
KNK. Newbold
K. Newbold

20 August 2021
Verified
Journal Article
Closed access
JSJames Peter Stewart
James Peter Stewart
JGJana Gazdova
Jana Gazdova
NDNikos Darzenta
Nikos Darzenta
DWDorte Wren
Dorte Wren
PPPaula Proszek
Paula Proszek
DGDavid Gonzalez
David Gonzalez
Current diagnostic standards for lymphoproliferative disorders include multiple tests for detection of clonal immunoglobulin (IG) and/or T-cell receptor (TCR) rearrangements, translocations, copy-number alterations (CNAs), and somatic mutations. The EuroClonality-NGS DNA Capture (EuroClonality-NDC) assay was designed as an integrated tool to characterize these alterations by capturing IGH switch regions along with variable, diversity, and joining genes of all IG and TCR loci in addition to clinically relevant genes for CNA and mutation analysis. Diagnostic performance against standard-of-care clinical testing was assessed in a cohort of 280 B- and T-cell malignancies from 10 European laboratories, including 88 forrnalin-fixed paraffin-embedded samples and 21 reactive lesions. DNA samples were subjected to the EuroClonality-NDC protocol in 7 EuroClonality-NGS laboratories and analyzed using a bespoke bioinformatic pipeline. The EuroClonality-NDC assay detected B-cell donality in 191 (97%) of 197 B-cell malignancies and T-cell donality in 71 (97%) of 73 T-cell malignancies. Limit of detection (LOD) for IG/TCR rearrangements was established at 5% using cell line blends. Chromosomal translocations were detected in 145 (95%) of 152 cases known to be positive. CNAs were validated for immunogenetic and oncogenetic regions, highlighting their novel role in confirming donality in somatically hypermutated cases. Single-nucleotide variant LOD was determined as 4% allele frequency, and an orthogonal validation using 32 samples resulted in 98% concordance. The EuroClonality-NDC assay is a robust tool providing a single end-to-end workflow for simultaneous detection of B- and T-cell clonality, translocations, CNAs, and sequence variants.